The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, comments on the safety and feasibility of outpatient management of cytokine release syndrome (CRS) in patients with multiple myeloma (MM) treated with bispecific antibodies. At the Mayo Clinic, the outpatient practice has been updated to allow these patients to treat initial CRS at home using dexamethasone, reducing hospital resource utilization. A remote patient monitoring program generates alerts so that hospitalization or escalation of care can occur if necessary. The majority of alerts are urgent in nature and occur during the initial stages of step-up dosing. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
